Abstract
The invention relates to use of the natural cytotoxicity receptor NKp46 for preventing and treating diabetes, including type I diabetes (TID) and type 2 diabetes. In particular, the invention provides compositions comprising a fragment of the extracellular region of NKp46 for preventing the onset and progression of diabetes.
Original language | English |
---|---|
Patent number | US2012076753 |
IPC | A61P 37/ 02 A I |
Priority date | 18/03/10 |
State | Published - 29 Mar 2012 |